Determination of the Expression of Latent Epstein Barr Virus in Omani Nasopharyngeal Carcinoma Patients

Sheikha Nasser Said Al-Shidhani¹, Shadia Al-Sinawi², Maiya Al Bahri², Masoud Al Kindi³ and Mohamed Mabruk¹

¹Department of Allied Health Sciences, College of Medicine and Health Sciences, Sultan Qaboos University, Oman.
²Department of Pathology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
³Department of Pathology, Armed Forces Hospital, Muscat, Oman.
*Corresponding author E-mail: mabruk@squ.edu.om

https://dx.doi.org/10.13005/bpj/2121

(Received: 27 January 2021; accepted: 19 March 2021)

Nasopharyngeal carcinoma (NPC) is a rare malignant carcinoma that develops in the epithelial lining of the nasopharyngeal mucosa. It is the most common neoplasm of the nasopharynx and it is associated with many risk factors; one of them is Epstein-Barr virus infection. An Epstein-Barr virus is a tumorigenic herpes virus that infects and persists in B-lymphocytes without causing disease. This virus is associated with significant pathological conditions, such as benign and malignant lymphoproliferation. The aim of the present study is to determine Epstein-Barr encoded RNA 1&2 (EBER1,2) and latent membrane protein (LMP) expression in formalin-fixed paraffin-embedded tissue samples obtained from Omani patients diagnosed with nasopharyngeal carcinoma. Also, to identify the pattern and the type(s) of cells infected with EBV in nasopharyngeal carcinoma tissue samples obtained from Omani patients. Moreover, to compare the sensitivity of Immunohistochemistry and in-situ Hybridization for the detection of EBV in the nasopharyngeal carcinoma tissue sample. Thirteen formalin-fixed paraffin-embedded nasopharyngeal carcinoma tissue samples archived from the period 2010 to 2017, were obtained from the Pathology Departments of Sultan Qaboos University Hospital and the Armed Force Hospital. These tissue samples were processed using two different methods Immunohistochemistry (IHC) and In situ hybridization (ISH). Eleven out of thirteen NPC Omani patients were positive for EBV (84.61%) by either LMP-IHC or EBER-ISH. All cells stained positive for EBV in NPC tissue samples was of malignant type rather than normal cell type. EBV is mostly detected in patients in the age group of less than 50 years old. Also out of the 13 NPC patients, seven females (58.34%), and six males (46.15%) were positive for EBV. This study may provide evidence indicating an association between EBV and nasopharyngeal carcinoma. In addition, the detection of EBV in NPC obtained from Omani patients may encourage the physician to consider using anti-herpes virus drugs in the treatment of EBV positive NPC patients as an additional tool for the treatment of this kind of malignancy.

Keywords: Nasopharyngeal Carcinoma, Epstein Barr virus, Omani patients.
in 100,000) in most populations\(^3\), but it is relatively common in males of Western North Africa\(^4\). In Asian countries, 50 years old is generally the mean age of NPC patients\(^5\). In the Omani population, 40% of the total cases of NPC were reported from the capital city Muscat, and about 21% were reported from Ash Sharqiyah region\(^6\). Besides, 17% of cases were reported from both Al-Batinah and Dhofar regions\(^6\).

In high-risk areas, the undifferentiated carcinoma of nasopharyngeal type (UCNT) is the most dominant histopathological type\(^3\). Moreover, NPC associated risk factors include genetic susceptibility, Epstein Barr virus (EBV) infection, ecological risk factors\(^3,7\). Also, certain dietary factors such as salted fish consumption is another factor that may contribute to the development of NPC\(^6\). Elevated antibody titers against Epstein Barr virus and a certain human leukocyte antigen class I genotypes are considered as well as a risk factors of NPC\(^8\).

Epstein-Barr virus (EBV) was first identified in a biopsy culture obtained from Burkitt lymphoma patients in 1964\(^9\). EBV is a tumorigenic herpesvirus that infects and persists in B-lymphocytes without causing disease\(^9\). In most cases, infection with EBV remains latent; however, in a few cases, it is associated with significant pathological conditions, such as benign and malignant lymphoproliferation\(^9\).

This virus has shown the ability to contribute to oncogenesis as it frequently detected in tumour tissue samples like Burkitt lymphoma, Hodgkin’s disease, and post-transplant B cell lymphomas\(^10\). In UCNT (The undifferentiated carcinoma of nasopharyngeal type), the EBV infection presents at an early stage of tumour development, which is evident by the usual presence of the EBV genome in a circular and monoclonal episomal form in the tumour cells\(^11\).

Latent membrane protein 1 (LMP1) which is a critical EBV oncogene\(^3\), is a transmembrane protein with two important properties, the first is its potent cell signalling properties and the second is the tumorigenic transformation properties\(^12\). LMP1 is capable of inducing cancer progenitor cell-like phenotyping in epithelial cells, which may contribute to the progression of nasopharyngeal carcinoma\(^13\). Transformation and immortalization of cells by LMP1 is done through directing the signalling pathways that stimulate cell proliferation and block apoptosis\(^14\). Many different downstream pathological changes can be caused by LMP1 including cell proliferation, apoptosis and metastasis\(^15\). LMP1 has the capabilities of activating several oncogenic signalling pathways such as NF-kB, JNK and MAPK\(^15\).

Epstein-Barr virus-encoded RNA (EBER), which have two types EBER1 and EBER2, is a non-polyadenylated untranslated RNAs of 167 (EBER1) and 172 (EBER2) nucleotides long, and it is transcribed by RNA polymerase III\(^16\). Besides, both EBER1 and EBER2 contribute to the oncogenesis of EBV, the transforming ability of recombinant EBVs expressing EBER2 was as high as that of EBVs expressing both EBER1 and EBER2\(^17\). The way by which EBERs contribute to the efficient growth transformation of B-lymphocytes is by enhancing the growth potential of the transformed lymphocytes\(^16\).

**MATERIALS AND METHODS**

**Specimens**

Thirteen formalin-fixed paraffin-embedded nasopharyngeal carcinoma tissue samples collected and archived from the period 2010 until 2017, were included in the present study. These samples were obtained from the Pathology Departments of SQUH and the Armed Force Hospital in Muscat/Oman. Also, the patient information including diagnosis, age, gender and MRN of each sample was recorded. The research ethical approval for the present study was obtained from the Research Ethics Committee of the College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman (MREC # 1495).

**Tissue processing**

Tissue processing for both Immunohistochemistry (IHC) and in situ hybridization (ISH), were carried out as described previously\(^18,19\). Briefly, the nasopharyngeal carcinoma formalin-fixed paraffin-embedded tissue samples were cut into sequential 4 µm sections using the microtome (Thermo Scientific).

From each tissue sample, 3 sections were cut and one was used for Haematoxylin and Eosin staining (H&E) and the other 2 sequential sections bounded covalently to the glass slides, where one was used for in situ hybridization (ISH) and the
other one was used for Immunohistochemistry (IHC) analysis. After sectioning the slides were incubated in 60 °C oven for one hour.

Positive controls consisted of Hodgkin Lymphoma tissue sample was included in each experiment. In addition, a negative control, was included in each experiment in which the primary antibody /EBERs probe was omitted and replaced with a buffered saline.

**Immunohistochemistry**

Immunohistochemistry was carried out on nasopharyngeal carcinoma tissue (NPC), samples using the Envision Flex+ High pH (Ref K8002, Dako) in accordance with the manufacturer’s instructions. Prior to staining the sections were deparaffinized twice through two changes of xylene, each xylene change was carried out for 5 minutes. Then, sections were hydrated in three changes of graded ethanol, each for 5 minutes followed by heat-induced epitope retrieval using the target high pH solution in the detection kit according to the package insert for the primary antibody. Subsequently, tissue sections were incubated in EnVision Flex Peroxidase-Blocking Reagent (SM801) for 10 minutes to block the endogenous peroxidase activity. This was followed by washing in Envision Flex Wash Buffer (TBS-DM831) (Dako, Denmark) for 5 minutes. Immunohistochemistry on processed tissue sections was carried out by the incubation of NPC tissue sections for 60 minutes at 37°C with primary antibody consisted of mouse monoclonal antibody against EBV-encoded LMP (clone: CS, 1-4 and isotype: IgG1, kappa, Dako, Denmark), followed by incubation at room temperature for 30 minutes with biotinylated secondary antibody. The secondary polyclonal antibody used in the present study consisted of dextran coupled with peroxidase molecules (Dako Envision Flex/HRP SM802). Then, 3,3-diaminobenzidine tetrahydrochloride (DAB) was add as a chromogen. The DAB chromogen gave a brown colour stain over the target site (EBV LMP protein). Mayer’s Haematoxylin stain was used as a counterstain.

**In situ hybridization (ISH)**

The expression of EBER1 and EBER2 of EBV in NPC tissue samples was carried out by using the Inform EBER Probe (800-2842, Ventana Medical Systems, Roche Diagnostics GmbH, Mannheim Germany). The EBERs positive signals in tissue samples were detected by Ventana ISH/View Blue detection Kit (Ref: 853-2193). In situ hybridization experiment was performed using (Ventana Bench Mark Ultra, Medical Systems Inc, Tucson, AZ, USA) following manufacturer instructions.

**Data analysis**

SPSS version 23 was used for data analysis. Frequency tables and pie charts or bar charts have been used to display percentages for categorized variables, and continuous variables have been shown as Mean ± SD and error bar charts. For the analysis, to test the significance of the association between categorized variables, the chi-square test was used.

**RESULTS**

**Epstein-Barr virus (EBV) expression in NPC tissue samples**

![Image A: ISH demonstrating, positive signals for EBER-EBV appear as purple color stain (red arrowhead). B: IHC demonstrating positive signals for EBV-LMP appearing as brown color stain (red arrowhead).]
The expression of Epstein-Barr virus (EBV) was detected in the present study by using two different technical approaches, *In-situ* hybridization for the detection of EBER and Immunohistochemistry for the detection of LMP protein of EBV in formalin-fixed paraffin-embedded NPC tissue samples obtained from Omani patients.

The results for the expression of EBV-LMP and the expression of EBV-EBER are summarized in Table 1. Positive cases were considered positive if they are positive by either one of the techniques (ISH or IHC). Eleven out of thirteen NPC Omani patients’ tissue samples were positive for EBV (84.61%) by either LMP-IHC or EBER-ISH; five of them were positive by both LMP-IHC and EBER-ISH (about 38.46%) while four of them were positive only by EBER-ISH (about 30.76%). Also, one of the cases was positive by LMP-IHC only. The results of EBER-ISH and LMP-IHC NPC positive cases are shown in Table 1 and Figure 1. The EBV positive NPC tissue samples detected by EBER-ISH (69.23%) is higher than that of LMP-IHC (53.84%). This may indicate that the sensitivity and specificity of EBER-ISH are higher than that of LMP-IHC for the detection of EBV.

The staining pattern of EBV expression/lymphocytic infiltration

The pathological examination of the NPC tissue sections stained with Haematoxylin and Eosin and the interpretation of IHC and ISH results was carried out by independent Pathologist. In the seven positive cases, latent Membrane

| Table 1. The expression of EBER and LMP in Nasopharyngeal carcinoma in Omani patients |
|---------------------------------------------|-----------------|-----------------|-----------------|
| EBER-EBV positivity by ISH (%)             | LMP-EBV positivity by IHC (%) | Total positive cases | Total number of cases |
| 9 (69.23%)                                  | 7 (53.84%)                    | 11 (84.61%)                  | 13 (100%)                      |

| Table 2. The integrity of staining, staining patterns and the type cells stained positive by LMP-EBV |
|---------------------------------------------|-----------------|-----------------|-----------------|
| Cases                                      | Integrity of staining | Staining pattern | Type of cells stained positive |
| Case 1                                     | Mild             | Cytoplasmic and Membranous | Malignant cells |
| Case 2                                     | Moderate         |                             | Malignant cells |
| Case 3                                     | Moderate         |                             | Malignant cells |
| Case 4                                     | Mild             |                             | Malignant cells |
| Case 5                                     | Strong           |                             | Malignant cells |
| Case 6                                     | Moderate (patchy)|                             | Malignant cells |
| Case 7                                     | Mild             |                             | Malignant cells |

| Table 3. The integrity of staining, staining patterns and the type cells stained positive by EBER-EBV |
|---------------------------------------------|-----------------|-----------------|-----------------|
| Histo#                                      | Integrity of staining | Staining pattern | Type of cells stained positive |
| Case 1                                     | Strong           | Nuclear          | Malignant cells |
| Case 2                                     | Strong           | Nuclear          | Malignant cells |
| Case 3                                     | Strong           | Nuclear          | Malignant cells |
| Case 4                                     | Strong           | Nuclear          | Malignant cells |
Protein (LMP) staining of EBV was Cytoplasmic and Membranous [Figure.1: B, Figure.2: C, E,G] [Table.2], while in EBER positive cases the staining pattern was Nuclear [Figure.1:A; Table.3]. The integrity of the staining in LMP-IHC ranges from mild to moderate to strong (Table 2; Figure.2: C, E, G]; however, strong staining integrity was seen in EBER-ISH [Table.3; Figure.1:A]. In addition, all cells stained positive by both ISH and IHC was of malignant type rather than normal cell type. Examples of staining pattern of EBER-ISH and LMP-IHC positive cases are shown in Figures.1,2.

The degree of lymphocytic infiltration in correlation to positive and negative cases was detected. Mild to moderate (7.143%), moderate (35.71%), and moderate to severe (7.143%) lymphocytic infiltration was observed in positive cases with LMP-IHC, while negative cases showed a similar degree of sparse, mild, and moderate of lymphocytic infiltration(16.67%) [Figure 2A]. Also, Haematoxylin and Eosin stain for NPC tissue.

Fig. 2. Nasopharyngeal carcinoma tissue samples, A: lymphocytic infiltration (HE Stain) (40X), B: positive control (Hodgkin lymphoma) for LMP-IHC (40X), C: Strong positivity for LMP-IHC (60X), D: Negative control for C (60X), E: Moderate positivity for LMP-IHC (60X), F: Negative control for E (60X), G: Weak positivity for LMP-IHC (60X), H: Negative control for G (60X)
samples showed a fibro collagenous tissue densely infiltrated by lymphocytes [Figure.2: A].

**EBV gene expression in correlation to age and gender**

Thirteen NPC patients (from 2010-2017) were divided into two age groups, < 50 years old and ≥50 years old. The first group (< 50 years) includes seven cases, four of them were positive for LMP-IHC (57.14%), while five of them were positive for EBER-ISH (71.42%). The second age group (≥50 years) included 6 cases, three of them were positive for LMP-IHC (50%), and four of them were positive for EBER-ISH (66.66%) [Table.4] [Figure.3]. The P-Value for both positivity by LMP-IHC and EBER-ISH shows a value higher than 0.05, which means that the

| Age     | Number of Cases | LMP-EBV Positivity by IHC (%) | EBER-EBV Positivity by ISH (%) |
|---------|-----------------|------------------------------|-------------------------------|
| < 50 years | 7               | 4 (57.14%)                   | 5 (71.42%)                    |
| ≥ 50 years | 6               | 3 (50%)                      | 4 (66.66%)                    |
| Total   | 13              | 7                            | 9                             |
| P-value | 0.797           | 0.853                        |                               |

**Table 4. The frequency of EBV positive cases in NPC (2010-2017) in correlation with age**

| Gender | Number of Cases | LMP-EBV Positivity by IHC (%) | EBER-EBV Positivity by ISH (%) |
|--------|-----------------|------------------------------|-------------------------------|
| Female | 7               | 5 (71.42%)                   | 6 (85.71%)                    |
| Male   | 6               | 2 (33.33%)                   | 3 (50%)                       |
| Total  | 13              | 7                            | 9                             |
| P-value| 0.17            | 0.164                        |                               |

**Table 5. The frequency of EBV positive cases in NPC (2010-2017) in correlation with Gender**
association between the age and the positivity of both LMP and EBER is not statistically significant.

In relation to gender, out of the thirteen cases included in this study seven of them were female, and the rest six were males. Five out of the seven females were positive for LMP-IHC (71.42%), while six of them were positive for EBER-ISH (85.71%). In the male’s category, two of them were positive for LMP-IHC (33.33%), and three of them were positive for EBER-ISH (50%). [Table.5] [Figure.3]. The P-Value for both positivity by LMP-IHC and EBER-ISH shows a value higher than 0.05, which means that the association between the gender and the positivity of both LMP and EBER is not significant.

**DISCUSSION**

Nasopharyngeal carcinoma has a very rare incidence (less than 1 in 100,000) in most populations. The mean age of developing NPC worldwide is of 50 years old in most Asian countries. In contrast, this study shows that the mean age of Omani patients with NPC was 47 years old, which could be considered close to that of Asian countries. The number of samples in the present study (Thirteen cases) demonstrates the very rare incidence of this type of malignancy in Oman.

There are different techniques used for the detection of Epstein-Barr virus (EBV), including immunohistochemistry (IHC), in situ hybridization (ISH), and polymerase chain reaction (PCR). The present study showed that eleven out of thirteen NPC Omani patients were positive for EBV by either LMP-IHC or EBER-ISH (84.6%), however, the positivity of EBER-ISH (69.23%) is higher than that of LMP-IHC (53.84%). This indicates that the sensitivity and specificity of EBER-ISH are higher than that of LMP-IHC for the detection of EBV. However, these findings are not of that significant as this could be due to the low number of samples used in the present study. This finding is similar to some degree to the finding of another study, which showed that EBER-ISH is more sensitive and more reliable than LMP-IHC for the detection of EBV in formalin-fixed paraffin-embedded tissue samples.

Most of the EBV positive cases were found in female category (58.34%), precisely out of the thirteen cases included in the present study seven of them were female, and the rest six were males (46.15%). This shows that EBV associated Nasopharyngeal carcinoma is more common in females than males among patients in Oman. This is different from the findings of other studies, which found that EBV is more prevalent in male NPC patients than females. However, in the present study, the P-Value for both positivity by LMP-IHC and EBER-ISH in correlation to age and gender shows a value higher than 0.05, which indicates that the association between the age and the gender and the positivity of both LMP and EBER is statistically non-significant. In addition, the results of the present study, show that EBV associated nasopharyngeal carcinoma are more prevalent in patients with the age of less than 50 years old (53.84%) in comparison to the age group ≥ 50 years old (46.15%). This is similar to a study carried out on the Sudanese population which found that the EBV associated NPC were seen mostly among the age group of 21-40 years old. Moreover, in the present study, all cells stained positive was of malignant type rather than normal cell type. This may indicate a relation between Epstein Barr Virus (EBV) and the pathogenesis of nasopharyngeal carcinoma.

The degree of lymphocytic infiltration ranged from sparse to mild to moderate to severe in some cases. In addition, the results of the present study showed that there was a correlation between the positivity for LMP-IHC and the degree of lymphocytic infiltration; where a higher degree of lymphocytic infiltration was detected in positive cases for LMP-IHC. Similarly, other studies validate this correlation between the positivity of EBV and the consistency of lymphocytic infiltration.

In conclusion, this study aimed to determine the expression of latent Epstein-Barr virus in Omani nasopharyngeal carcinoma patients. The importance of this study originated from the need to determine the prevalence of EBV in Omani patients with NPC especially that the prevalence of latent EBV infection is considered as a risk factor of NPC. The present study showed a clear association between EBV and NPC among Omani patients, especially, that all cells stained positive for EBV was of malignant type rather than normal cell type. This indicates that EBV infection may play a role in the pathogenesis of NPC. The detection of
EBV in NPC obtained from Omani patients may encourage the physician to consider using anti-herpes virus drugs in the treatment of EBV positive NPC patients as an additional tool for the treatment and the management of this kind of malignancy.

ACKNOWLEDGEMENTS

The authors would like to thank the head and all the staff at the Department of Pathology at Sultan Qaboos University Hospital for their help and support and for allowing us to use their Departmental and laboratory facilities. The authors would also like to thank the Pathology Department/Armed Force Hospital for all of their help and support.

Conflict of interest

The authors declare no conflict of interest

Funding source

The present study was not funded by any grant.

REFERENCES

1. Borthakur P, Kataki K, Keppen C, Khamo V, Medhi D, Deka M. Expression of Epstein Barr Virus Encoded EBNA1 and LMP1 Oncoproteins in Nasopharyngeal Carcinomas from Northeast India”. Asian Pacific Journal of Cancer Prevention 17(7): 3411-341 (2016)
2. Beena U, and Ahmed R. “Nasopharyngeal Carcinoma, An Analysis Of Histological Subtypes And Their Association With EBV, A Study Of 100 Cases Of Pakistani Population”. Asian Journal of Medical Sciences 5(4): 16-20(2014).
3. Banko A, Lazarevic I, Folic MM. Characterization Of The Variability Of Epstein-Barr Virus Genes In Nasopharyngeal Biopsies: Potential Predictors For Carcinoma Progression”. PLOS ONE11(4):1-16 (2016): e0153498.
4. Bernadette B Nasopharyngeal Carcinoma”. Orphanet Journal of Rare Diseases: 1:23. (2006). doi:10.1186/1750-1172-1-23
5. Gamoudi A, Fourati A, BiazzigN. Complementary Determination Of Epstein-Barr Virus DNA Load And Serum Markers For Nasopharyngeal Carcinoma Screening And Early Detection In Individuals At Risk In Tunisia”. European Archives of Oto-Rhino-Laryngology 269(3): 1005-1011(2012).
6. Al-Azri, Abdulaziz, and Salma Al-Sheibani. “Nasopharyngeal Carcinoma In Oman: A Descriptive Analysis”. Oman Medical Journal30(3): 167-172(2015).
7. Ahmed GD, Suliman RS, El Aziz Mand, Alshammar FD. Molecular Detection Of Epstein-Barr Virus In Nasopharyngeal Carcinoma Among Sudanese Population”. Infectious Agents and Cancer11(1): 1-5(2016)
8. Chang, E. and Adami, H. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. [online] Cancer Epidemiol Biomarkers Prev; 15(10):1765-1777(2006)
9. Williams, H., and Dorothy H. Crawford. “Epstein-Barr Virus: The Impact Of Scientific Advances On Clinical Practice”. Blood107(3): 862-869(2006)
10. Young, Lawrence S, and Paul G. Murray, “Epstein–Barr Virus And Oncogenesis: From Latent Genes To Tumours”. British Journal of Haematology142(1): 79-81(2008).
11. Jun Zhang , Lin Jia, Weitao Lin , Yim Ling Yip , Kwok Wai Lo , Victoria Ming Yi Lau, Sai Wah Tsao. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription Via The Mtorc1/NF-Kb Signaling Pathways. Journal of Virology91(6): 1-20(2017).
12. He, Jiang. Positive Regulation Of TAZ Expression By EBV-LMP1 Contributes To Cell Proliferation and Epithelial-Mesenchymal transition In Nasopharyngeal Carcinoma”. Oncotarget; 8(32): 52333–52344.
13. Lu, J., Tang, M., Li, H., Xu, Z., Weng, X., Li, J., Yu, X., Zhao, L., Liu, H., Hu, Y., Tan, Z., Yang, L., Zhong, M., Zhou, J., Fan, J., Bode, A. M., Yi, W., Gao, J., Sun, L., & Cao, Y. (2016). EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. Cancer Letters, 380(1), 191-200. https://doi.org/10.1016/j.canlet.2016.05.032(2016).
14. Yajima, M., Kanda, T. and Takada, K. Critical Role Of Epstein - Barr virus (EBV)-Encoded RNA In Efficient EBV-Induced B-Lymphocyte Growth Transformation. Journal of Virology; 79(7):4298-4307 (2005).
17. Wu, Y., Maruo, S., Yajima, M., Kanda, T. and Takada, K.. Epstein-Barr virus (EBV)-Encoded RNA 2 (EBER2) but Not EBER1 Plays a Critical Role in EBV-Induced B-Cell Growth Transformation. *Journal of Virology*; **81**(20): 11236-11245 (2007)

18. Mabruk, M., Flint, S., Coleman, D., Shiels, O., Toner, M. and Atkins, G. A rapid microwave-in situ hybridization method for the definitive diagnosis of oral hairy leukoplakia: comparison with immunohistochemistry. *Journal of Oral Pathology and Medicine*; **25**(4):170-176 (1996).

19. Yunos A, Mabruk M. “Detection Of Epstein-Barr Virus In Lower Gastrointestinal Tract Lymphomas”. *Molecular Diagnosis & Therapy*; **10**(4): 251-256 (2006).

20. Nonogaki, S., Shirata, N., Kimura, L., Guerra, J., Medeiros, R., Paes, R., Kanamura, C., Oliveira, C. and Menezes, Y. Comparative study of five commercial probes for the detection of Epstein-Barr virus (EBV) by in situ hybridization in cases of nodular sclerosis Hodgki’s lymphoma. *Jornal Brasileiro de Patologia e Medicina Laboratorial*. *Jornal Brasileiro de Patologia e Medicina Laboratorial* **52**(6). 10.5935/1676-2444.20160065; (2016)

21. Chu, P., Chang, K., Chen, Y., Chen, W. and Weiss, L.. No Significant Association of Epstein-Barr Virus Infection with Invasive Breast Carcinoma. *The American Journal of Pathology*; **159**(2):571-578 (2001).

22. Abe, T., Shinohara, N., Tada, M., Harabayashi, T., Sazawa, A., Maruyama, S., Moriuchi, T., Takada, K. and Nonomura, K.. Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers. *International Journal of Urology*; **15**(5):429-434 (2008).